ID   MB49-I
AC   CVCL_VL62
DR   Wikidata; Q95985487
RX   PubMed=19539312;
RX   PubMed=22559978;
RX   PubMed=29732388;
RX   PubMed=30867744;
CC   Characteristics: Has an invasive and metastatic phenotype.
CC   Characteristics: Established after 13 consecutive passages of MB49 through subcutaneous injection in the left flank of C57BL/6J male mice.
CC   Karyotypic information: Has lost chromosome Y (PubMed=22559978).
CC   Transformant: ChEBI; CHEBI:59032; 7,12-dimethyltetraphene (DMBA; dimethylbenzanthracene).
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
CC   Breed/subspecies: C57BL/ICRF-a(t).
DI   NCIt; C25823; Mouse bladder transitional cell carcinoma
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_7076 ! MB49
SX   Male
AG   Adult
CA   Cancer cell line
DT   Created: 07-09-18; Last updated: 29-06-23; Version: 6
//
RX   PubMed=19539312; DOI=10.1016/j.juro.2009.03.076;
RA   Lodillinsky C., Rodriguez V., Vauthay L., Sandes E., Casabe A.,
RA   Eijan A.M.;
RT   "Novel invasive orthotopic bladder cancer model with high cathepsin B
RT   activity resembling human bladder cancer.";
RL   J. Urol. 182:749-755(2009).
//
RX   PubMed=22559978; DOI=10.1016/j.cancergen.2012.02.002;
RA   Fabris V.T., Lodillinsky C., Pampena M.B., Belgorosky D., Lanari C.,
RA   Eijan A.M.;
RT   "Cytogenetic characterization of the murine bladder cancer model MB49
RT   and the derived invasive line MB49-I.";
RL   Cancer Genet. 205:168-176(2012).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//
RX   PubMed=30867744; DOI=10.3892/ol.2019.9995;
RA   Alberto M., Cuello H.A., Gulino C.A., Pifano M., Belgorosky D.,
RA   Gabri M.R., Eijan A.M., Segatori V.I.;
RT   "Expression of bladder cancer-associated glycans in murine tumor cell
RT   lines.";
RL   Oncol. Lett. 17:3141-3150(2019).
//